$AngioDynamics (ANGO.US)$ NEWS AngioDynamics Announces CE Ma...
NEWS
AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System
AngioDynamics (NASDAQ: ANGO) has received CE Mark approval in Europe for its AlphaVac F1885 System. This regulatory milestone allows the company to market the mechanical thrombectomy system for non-surgical removal of thrombi or emboli from the pulmonary arteries, aiding in the treatment of pulmonary embolism (PE). The system aims to improve patient outcomes in the EU, where PE has a higher prevalence compared to the U.S. In December 2023, AngioDynamics completed patient enrollment for its U.S.-based APEX-AV trial, which showed significant decreases in RV/LV ratios and clot burdens, with a low Major Adverse Event rate.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
959Followers
63Following
6463Visitors
Follow